Claims
- 1. An isolated polypeptide comprising amino acids at least 85% identical to amino acids selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted, wherein said polypeptide binds to and negatively regulates CIF150/hTAFII150.
- 2. The polypeptide of claim 1 wherein said polypeptide is at least 90% identical to amino acids selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted.
- 3. The polypeptide of claim 1 wherein said polypeptide is at least 95% identical to amino acids selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted.
- 4. An isolated polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted, wherein said polypeptide binds to and negatively regulates CIF150/hTAFII150.
- 5. An isolated polypeptide comprising amino acids selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted, wherein said polypeptide binds to and negatively regulates CIF150/hTAFII150.
- 6. An isolated epitope-bearing portion fragment of the polypeptide of SEQ ID NO:2.
- 7. The epitope-bearing portion fragment of claim 6, which consists of between about 6 and about 20 contiguous amino acids of SEQ ID NO:2.
- 8. The epitope-bearing fragment of claim 7, which consists of about 10 contiguous amino acids of SEQ ID NO:2.
- 9. A CIF130 fusion protein comprising a first protein segment and a second protein segment fused together by means of a peptide bond, wherein the first protein segment comprises amino acids at least 85% identical to amino acids selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted, wherein said fusion protein binds to and negatively regulates CIF150/hTAFII150.
- 10. A CIF130 fusion protein comprising a first protein segment and a second protein segment fused together by means of a peptide bond, wherein the first protein segment comprises amino acids selected from the group consisting of:(a) amino acids about 1 to about 1261 of SEQ ID NO:2; (b) amino acids about 46 to about 1261 of SEQ ID NO:2; (c) amino acids about 165 to about 1261 of SEQ ID NO:2; (d) amino acids about 165 to about 585 of SEQ ID NO:2; (e) amino acids about 165 to about 698 of SEQ ID NO:2; (f) amino acids about 165 to about 819 of SEQ ID NO:2; and (g) the amino acids of any of (a) through (f) in which amino acids 175 to 186 are deleted, wherein said fusion protein binds to and negatively regulates CIF150/hTAFII150.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of U.S. patent application Ser. No. 09/332,295 filed Jun. 11, 1999, now U.S. Pat. No. 6,303,372, which application claims the benefit of provisional applications Ser. No. 60/089,198 filed Jun. 12, 1998, and Ser. No. 60/111,636 filed Dec. 9, 1998, which are incorporated by reference herein in their entirety.
Foreign Referenced Citations (2)
Number |
Date |
Country |
WO 9933985 |
Jul 1999 |
WO |
WO 9964450 |
Dec 1999 |
WO |
Non-Patent Literature Citations (6)
Entry |
Kaufmann and Smale, “Direct recognition of initiator elements by a component of the transcription factor IID complex,” Genes & Development 8: 821-829, 1994. |
Kaufmann et al., “CIF150, a Human Cofactor for Transcription Factor IID-Dependent Initiator Function,” Molecular And Cellular Biology 18(1): 233-239, 1998. |
Kaufmann et al. “CIF, an essential cofactor for TFIID-dependent initiator function,” Genes & Development 10: 873-886, 1996. |
Sukegawa et al., “A Putative Mammalian RNA Helicase with Arginine-Serine-Rich Domain Colocalizes with a Splicing Factor,” J. Biol. Chem. 270: 15702-15706, 1995. |
Sukegawa et al., EMBL Sequence Database, Accession No. ACQ62780, Nov. 1, 1996. |
Suk et al., EMBL Sequence Database, Accession No. ACO75619, Nov. 1, 1998. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/089198 |
Jun 1998 |
US |
|
60/111636 |
Dec 1998 |
US |